In LTK
Dopamine is an endogenous catecholamine that exerts its actions by occupancy of specific receptors. Based on pharmacological and biochemical studies, dopamine receptors were classified initially into two main groups: the dopamine receptor linked to stimulation of adenylyl cyclase (D 1 ), and the dopamine receptor not linked to adenylyl cyclase or linked to its inhibition (D 2 ). The cloned dopamine receptors fall into these two groups. Thus, in mammals, the two D 1 (6, 7) . Another D 1 -like receptor has also been linked to stimulation of PLC 1 activity (8 -14) , whereas the D 2 receptor can be linked to inhibition or stimulation of PLC depending on the cell that expresses it (15, 16) .
Several PLC isoenzymes have been purified, molecularly cloned, and sequenced (17, 18) . These isoforms have been grouped into three families: PLC-␤, PLC-␥, and PLC-␦, with several members in each (e.g. PLC-␤ 1 , PLC-␤ 2 , PLC-␤ 3 , PLC-␤ 4 ). They are linked to G proteins and tyrosine kinases (17) (18) (19) (20) (21) (22) (23) (24) . The G q family of G proteins, which are pertussis toxin-insensitive, has been linked to activation of PLC-␤ 1 , whereas tyrosine kinases activate PLC-␥ 1 . PLC-␤ isoforms (PLC-␤ 3 Ͼ PLC-␤ 2 Ͼ PLC-␤ 1 ) can also be activated by G protein ␤/␥ subunits independent of G-protein ␣ subunits, PLC-␤ 4 being an exception (18, 25) . We reported recently the linkage of dopamine and ␣-adrenergic receptors to PLC isoforms in renal cortical tissue (26) . We found that a 3-4-h intravenous or intrarenal arterial infusion of norepinephrine or a D 1 agonist, which produces an anti-natriuresis or natriuresis, respectively, increases PLC-␤ 1 and activity in renal cortical membranes similar to other G q protein-linked receptors (24, 26) . We also found that G protein-linked receptors alter the protein level and activity of PLC-␥ 1 (26) , confirming an earlier report (27) . Thus, we reported that infusion of two chemically unrelated dopamine receptor agonists, the D 1 agonist fenoldopam and the D 1 /D 2 /D 3 receptor agonist pramipexole, decreases PLC-␥ protein and activity in the membrane. Norepinephrine infusion, on the other hand, increases PLC-␤ 1 protein and activity but does not affect PLC-␥ activity in the membrane. These actions of dopamine agonists do not occur in medullary membranes. Furthermore, there are no effects of dopamine agonists on PLC-␦ in either cortex or medulla. The putative D 1 receptor linked to PLC stimulation is yet to be cloned. Initial studies with the cloned D 1 -like receptors (D 1A , D 1B , D 1C , D 1D ) failed to show linkage with PLC (1-4, 6, 7). However, the human, rat, and goldfish D 1A receptors were found to stimulate phosphoinositol hydrolysis or increase intracellular calcium (28, 29) . In the current studies, we determined that the D 1A receptor stimulates a specific isoform of PLC and elucidated the mechanism of this stimulatory effect.
EXPERIMENTAL PROCEDURES
Materials-Monoclonal antibodies to the PLC isozymes and PKC were purchased from Upstate Biotechnology Inc., Lake Placid, NY.
Forskolin, S p -8-CTP-cAMP, phorbol 12-myristate 13-acetate (PMA), and calphostin C were from Calbiochem. , and HEKD 1A , respectively) as described (30) . The LTK Ϫ D 1A cells were maintained in ␣-minimal essential medium supplemented with 10% fetal bovine serum and geneticin (0.25 mg/ml) under a humidified atmosphere of 95% air and 5% CO 2 at 37°C. The cells were subcultured for the experiments by planting them at approximately 10 5 cells/ml in a 100-mm tissue culture dish. At Ϸ70% confluence, the cells were placed in the medium containing 10 mM butyric acid, pH 7.2, and cultured for another 48 h (30) . In LTK Ϫ D 1A cells, the B max was 0.23 Ϯ 0.13 pmol/mg of protein, and the K d was 1.35 Ϯ 0.56 nM (n ϭ 2) performed in triplicate. The B max is close to that found in renal proximal tubules (31) . After washing twice with phosphate-buffered saline, they were incubated for the indicated time periods at 37°C with various drug concentrations in ␣-minimal essential medium containing 1% dialyzed fetal bovine serum. The incubations were then terminated by washing with ice-cold phosphate-buffered saline three times, and the cells were lysed by adding lysis buffer containing (in mM) 20 Tris-HCl, pH 7.4, 2 EDTA, 2 phenylmethylsulfonyl fluoride, 25 sodium pyrophosphate, 20 sodium fluoride, and 10 g/ml each leupeptin and aprotinin. The cells were sonicated for a few seconds and centrifuged at 14,000 rpm for 20 min at 4°C; the supernatant represented the cytosol. The pellets were extracted by the addition of lysis buffer containing 1.0% sodium cholate for membrane PLC assays or containing 1.0% Triton X-100 for membrane PKC assays.
Measurement of PLC Activity-The cytosol and membranes were assayed for PLC activity according to the method of Nishibe et al. (32) . In brief, the assay was performed in a 50-l reaction mixture containing 30,000 cpm of [ The reactions proceeded for 15 min at 37°C and were terminated by adding a stop solution containing 100 l of 1% bovine serum albumin and 500 l of 10% trichloroacetic acid. PIP 2 -hydrolyzing radioactivity was determined by liquid scintillation counting. PLC activity was expressed as cpm/mg of protein/min.
Measurement of PKC Activity-The cell preparations were assayed for PKC activity by a PKC-ELISA kit. Samples were preincubated at 25°C in water bath for 5 min with PKC assay buffer containing 0.3 mM ATP and phosphatidylserine. The mixture was transferred to an ELISA plate that was coated with glial fibrillary acidic protein and allowed to incubate for another 5 min. The plate was then incubated with mouse monoclonal antibody YC-10 after three washings. The resulting immunocomplexes were detected by peroxidase conjugated to secondary antibody, and the intensity of the color was measured photometrically at 450 nm.
Determination of Receptor Specificity-Since currently available D 1 antagonists do not have receptor subtype specificity, we determined the involvement of the D 1A receptor using antisense phosphorothioate oligodeoxynucleotides purified by high performance liquid chromatography (GENSET SA, Paris, France). Thus, sense (5Ј-ATG GCT CCT AA-C ACT TCT ACC-3Ј) (5 M) and antisense (5Ј-GGT AGA AGT GTT AGG AGC CAT-3Ј) (5 M) oligodeoxynucleotides were incubated with LTK Ϫ D 1A cells for 2 days in culture medium at 37°C. Following two washings, the cells were treated with vehicle or fenoldopam (5 M). The ability of antisense but not sense oligonucleotides to prevent the expression of the D 1A receptor was verified by immunocytochemistry using anti-D 1A antibodies directed against the third extracytoplasmic loop (33) . Immunoblot of PLC-Immunoblotting was performed as described previously (26) . Essentially, the proteins were separated by electrophoresis on 7.5% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and then transferred electrophoretically to nitrocellulose membranes. The transblots were probed with indicated antibodies and detected by peroxidase-labeled secondary antibody and chemiluminescence detection reagents. Quantification of the immunoblots was performed as reported with modifications (26); the density of the area of each immunoblot was quantified using Quantiscan (Biosoft, Ferguson, MO).
Measurement of Maximum Receptor Density (B max ) and Dissociation Constant (K d )-B

RESULTS
D 1 Agonist Induces PIP 2 Hydrolysis-To determine the effect of a D 1 agonist on PLC activity, LTK
Ϫ D 1A cells were stimulated with the selective D 1 agonist fenoldopam (SKF82526, 5 M), for indicated time periods, and PLC activity was measured. In the cytosol, PLC activity increased by up to 50 Ϯ 7% (n ϭ 5) in 30 s but slowly fell back to base line after 4 h. Similarly, in the membranes, PLC activity increased rapidly within 30 s (36 Ϯ 13%, n ϭ 5) and returned to baseline at 10 min. After a 24-h incubation, both cytosolic and membrane PLC activity decreased below base line (Fig. 1) . These data are similar to our previous in vivo studies (26) where PLC activity increased in cytosol and decreased in membranes following the intravenous infusion of fenoldopam for 3-4 h. Fenoldopam had no effect on PLC activity in nontransfected LTK Ϫ cells (Fig. 1) . Effect of Fenoldopam on PLC Protein and Activity-Mouse monoclonal antibodies specific to PLC isoforms which recognize mouse, rat, bovine, and human PLCs were used (34, 35) . In preliminary studies, we found that PLC-␥1 (145 kDa) and PLC-␦1 (85 kDa) but not PLC-␤1 were expressed in LTK Ϫ cells. Fenoldopam moderately increased PLC-␥1 protein in a timedependent pattern, which lasted longer in cytosol than in membranes ( Fig. 2A) receptor-mediated stimulation of PLC-␥ protein represents a direct mechanism or is secondary to adenylyl cyclase stimulation was addressed next. The stimulatory effect of fenoldopam on PLC-␥ and activity was blocked by the PKA inhibitor R pcAMP-S (50 M) (Fig. 4, A and B, respectively) , indicating involvement of PKA. In addition, this process also involved PKC since the PKC inhibitor calphostin C (10 nM) prevented the stimulatory effect of fenoldopam on PLC-␥ protein and activity (Fig. 4, C and D, respectively) . Another PKC antagonist, chelerythrine (10 M), had a similar effect but only in the membrane and not in the cytosol (data not shown). (Fig. 5, A and B) . The effect on PLC-␥ protein and activity in membranes was blocked by a PKA antagonist, R p -cAMP-S, but produced only a modest and nonsignificant attenuation in forskolin-induced increase in PLC activity in cytosol (Fig. 5B) . The PKA agonist S p -cAMP-S increased PLC activity in both cytosol and membrane, an effect that was blocked by R p -cAMP-S (Fig.  5C ). Thus, PKA is involved in stimulating PLC-␥ protein and activity, especially in membranes. In addition, PKC is also involved since the stimulatory effect of forskolin (200 M/20 min/37°C) was blocked by the PKC antagonist calphostin C (10 nM) (Fig. 5D ), although this achieved significance only in the membrane fraction. In addition, forskolin increased PKC-␣ in membrane, an effect that preceded the increase in PLC-␥ ( Fig.  5E ; three other experiments gave similar results). Forskolin (200 M/5 min/37°C) increased PKC activity by 32% in membranes (but not in cytosol); the increase in response to forskolin was blocked by calphostin C (10 nM) ( Table I ). The stimulatory effect of forskolin on PKC activity could also be mimicked by S p -8-CTP-cAMP (50 M), a nonhydrolyzable PKA activator (27 Ϯ 2%, n ϭ 6).
PMA Increases PLC-␥ Protein and Activity-Stimulation of (Fig. 6) and activity (Fig. 4D ) of PLC-␥ in membranes; this effect was blocked completely by calphostin C (10 nM) (Fig. 4D) . (28) . However, whether stimulation of PLC activity by D 1 agonists in these transfected cells was primary or secondary to stimulation of adenylyl cyclase activity was not determined. In this regard, the ability of D 1 agonists to stimulate phosphoinositide hydrolysis has been shown to be mediated by a cholera toxin-sensitive process (28) . The stimulatory effect of the thyrotropin-releasing hormone receptor expressed in Xenopus oocytes on PLC has also been shown to be coupled to G s (37) . G q is not involved since LTK Ϫ cells do not express PLC-␤, 2 the isoform that is linked to G q (19, 24) .
The current report confirms earlier findings (28) that short term stimulation of the D 1A receptor in transfected LTK Ϫ cells is linked to increased PLC-␥ protein and activity. The effect of the D 1 agonist fenoldopam on PLC-␥ protein and activity was time-dependent in both membrane and cytosol; the stimulatory effect on PLC activity was quite transient in membranes, and an inhibitory effect was noted after 24 h of incubation. The fenoldopam-induced changes in PLC activity were paralleled by similar changes in PLC-␥ protein; the effect on activity occurred earlier than the effect on protein. No changes in PLC-␦ protein were noted. These effects are mediated through PKA, since forskolin increased PLC-␥ protein, and a PKA inhibitor blocked the stimulatory effect of either fenoldopam or forskolin. The ability of D 1A receptors to increase PLC activity via cAMP is not unique to these receptors. Glucagon, calcitonin, muscarinic and ␤-adrenergic receptors, forskolin, AlF 4 Ϫ , and cAMP analogs 8-Br-cAMP and S p -8-CPT-cAMP have also been reported to stimulate phosphatidylinositol 1,4,5-trisphosphate production in hepatocytes, neuroepithelioma, and skeletal muscle cells (38 -40) . These studies suggested that the increase in phosphatidylinositol 1,4,5-trisphosphate production was secondary to elevation of cAMP. However, the PKC agonist PMA had an inhibitory effect in hepatic cells (39) , and these studies did not determine the mechanism by which cAMP enhances phosphoinositide hydrolysis. Although PKCs can regulate phosphatidylcholine-PLC, this pathway is not directly involved in our studies since the substrate used was PIP 2 , the substrate of phosphatidylinositol-specific PLC (41) .
In our studies, fenoldopam increased PLC-␥ protein via a PKA/PKC pathway (Fig. 7) . PKA stimulation of PKC probably mediates membranous PLC activation, since both forskolin and a PKA agonist increase PKC activity. The involvement of PKC in the activation of PLC-␥ is supported further by the observation that forskolin activates PKC-␣ prior to the stimulation of PLC-␥ protein. Moreover, PKC blockers prevent the stimulatory effect of fenoldopam, forskolin, or PMA on PLC-␥. This conclusion is particularly relevant to the studies in membranes. The ability of forskolin to increase PLC-␥ protein and activity was blocked by a PKA antagonist only in membrane but not in cytosol. However, the PKA agonist S p -cAMP-S increased PLC-␥ activity in both membrane and cytosol, effects that were blocked by a PKA antagonist. It is possible that effects of forskolin other than stimulation of cAMP production may stimulate PLC-␥ protein and activity by some other undefined pathway. PMA, which stimulated PLC-␥ protein in both membrane and cytosol, stimulated PLC activity only in the membrane fraction. The failure of PMA to increase PLC activ- ity in cytosol at a time when PLC-␥ protein increased is not understood. However, the PMA-induced increase in PLC-␥ protein in cytosol was not blocked by calphostin, suggesting that this effect may not be PKC-mediated.
Although the present finding indicates that PLC stimulation in these transfected cells is secondary to adenylyl cyclase stimulation, several studies in tissues have implicated the existence of a D 1 -like receptor that is linked to phospholipase activation independent of adenylyl cyclase (9, 11, 13, 14) . Activation of D 1 -like receptors decreases sodium transport by cAMP-dependent (42) (43) (44) and cAMP-independent mechanisms (45) (46) (47) (48) . For example, dopamine, via D 1 -like receptors, can inhibit Na ϩ /H ϩ exchange activity in renal brush-border membranes by a cAMPdependent and -independent/G s␣ -linked mechanism (48) . Another cAMP-independent pathway of sodium transport inhibition is mediated by PLC (45) (46) (47) . Thus, D 1 agonists stimulate PLC and PKC activity in renal cortical tubules and membranes (9, 49, 50) independent of adenylyl cyclase. cAMP-independent PLC stimulation by D 1 agonists has also been shown in the retina and striatum (12, 13) , although the latter remains controversial (51) . The effects of fenoldopam on PLC activity and protein in LTK Ϫ cells heterologously expressing the D 1A receptor have both similarities and differences compared with in vivo studies in the rat (26) . A 2-4-h infusion of dopaminergic drugs with agonist effects on D 1 -like receptors increased PLC-␥ activity and protein in cytosol but decreased it in membrane (26) ; the assay for PLC activity and immunoblotting were performed as described under "Experimental Procedures." Forskolin increased PLC-␥ protein and activity in both cytosol and membrane; the stimulatory effect of forskolin on PLC-␥ protein was prevented by R p -cAMP-S in membrane and cytosol (panel A, n ϭ 6). R p -cAMP-S also prevented the stimulatory effect of forskolin on PLC activity in membranes but only insignificantly attenuated it in the cytosol (panel B). However, R p -cAMP-S did block the stimulatory effect of the PKA agonist S p -cAMP-S on PLC activity in both cytosol and membrane (panel C, n ϭ 6). The stimulatory effect of forskolin on PLC-␥ protein also involved PKC since this action was prevented by calphostin in membrane (panel D, n ϭ 6). Data are the means Ϯ S.E. #p Ͻ 0.05 versus control; *p Ͻ 0.05 versus control or combination and p Ͻ 0.05 versus control or R p -cAMP-S, repeated measures ANOVA and Scheffe's test. In addition, forskolin increased PKC-␣, which preceded the in- 
D
1A cells. Cells were treated with 1 M PMA (f) or 10 nM calphostin (p) or both (s) for 20 min at 37°C, and immunoblotting was performed as described under "Experimental Procedures." Densitometric analysis of immunoblots shows that PMA increased PLC-␥ in membrane and modestly in cytosol, the effect in membrane was blocked by calphostin (n ϭ 6). Data are the means Ϯ S.E. *p Ͻ 0.05 versus control or combination, repeated measures ANOVA and Scheffe's test, ϩp Ͻ 0.05 versus control, paired t test.
ences. In rat studies, D 1 receptor stimulation of PLC activity at 4 h was linked to stimulation of PLC-␤ in membranes (26) . LTK Ϫ cells, however, do not express PLC-␤. It is, therefore, possible that a D 1 -like receptor uniquely linked to PLC-␤ isoform exits. In the kidney, this D 1 receptor is linked to a pertussis toxin-insensitive G protein (9) , presumably G q ; PLC-␤ is coupled to G q (19, 24) . Furthermore, in the striatum, the size of the mRNA associated with PLC stimulation and calcium mobilization is different from the transcripts of the cloned D 1 receptors (12) . A D 1 -like receptor that is not linked to either PLC or adenylyl cyclase activation but stimulates K ϩ efflux has also been reported (52) . It is possible that other as yet uncloned D 1 -like receptors exist including one that is linked primarily to PLC-␤ and independent of adenylyl cyclase.
In summary, D 1A receptors are linked to stimulation of both adenylyl cyclase and PLC activity. The early increase in PLC activity is associated with an increase in PLC-␥ protein. Based on the results of the present study, we suggest that D 1A -mediated stimulation of PLC occurs as a result of PKA activation. PKA then stimulates PLC-␥ protein in cytosol and membrane. The stimulatory effect on PLC-␥ in membrane is secondary to an increase in PKC activity (Fig. 7) . These findings cannot determine if there is a different D 1 -like receptor linked to PLC-␤ isoform since this isoform was not expressed in the cell lines in which the D 1A receptor was heterologously expressed.
